Skip to main content
AMCP 2025 Main banner
Back

Making the Way for Innovation

(W6) Understanding Complexities Specific to Gene Therapy and Navigating Available Management Strategies

Wednesday, April 2, 2025
4:15 PM – 5:30 PM CST
Location: 320
CPE
ACPE UAN:0233-0000-25-024-L04-P | Contact Hours: 1.25 | Activity Type: Knowledge-based
Using the term “gene therapy” can be a misleading blanket statement. Although gene therapies are regulated by the FDA, each gene therapy is uniquely complex. This unique complexity starts well before the therapy receives FDA approval. The rare orphan diseases involved, currently available treatment options, and the potential for curative outcomes impact how health plans and providers assess the associated emerging risks and navigate available solutions to mitigate those risks.

This session will explore the various complexities and risks that are associated with gene therapies. In addition, this session will review considerations in the management of gene therapies for financial and network optimization.

Learning Objectives:

At the completion of this activity, participants should be able to:
  1. Describe the complexities unique to the gene therapy market.
  2. Identify the risks associated with gene therapy by assessing the benefit structure, eligibility criteria, and forecast capabilities.
  3. Discuss key considerations in the management of gene therapies for financial and network optimization.